One of Illumina's complaints is that their data was "too white" (because for the most part affluent whites were the only ones who could afford to get sequenced). The push to cheapen the cost of clinical genomics a well as establish partnerships with companies like 23AndMe (who use Illumina's machines and facilities to do their sequencing) was pressed forward under the pretense of "establishing a better data set to identify rare and undiagnosed genetic disorders" by targeting more genetically diverse data by minorities that are not getting sequenced, today. I suspect their data set will be expanded at the taxpayer's expense by government subsidized funds because that's too juicy of a DNA database for the .GOV to pass up for it's spying machine. Illumina shareholders likely hope for the same thing to bloat their pocketbooks.